<DOC>
	<DOCNO>NCT00938327</DOCNO>
	<brief_summary>This post marketing surveillance evaluate reactogenicity safety data human rotavirus vaccine administer healthy infant accord Prescribing Information India .</brief_summary>
	<brief_title>Reactogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Rotarixâ„¢ ( Human Rotavirus Vaccine ) Indian Infants</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol enrolled PMS . A male female infant , age 6 week time first vaccination le 24 week age time second vaccination . Written inform consent obtain parent guardian subject . History allergic disease reaction likely exacerbate component vaccine . Concurrently participate another clinical study , time surveillance period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Acute disease time enrolment . Any history uncorrected congenital malformation gastrointestinal tract would predispose subject intussusception . Known hypersensitivity previous administration rotavirus vaccine component vaccine . Gastroenteritis within 7 day precede vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>167 Days</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Gastroenteritis</keyword>
</DOC>